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Background: Tramadol ((±)-TRA) is recommended for the treatment of mild to moderate cancer pain by the World
Health Organization. An oral liquid formulation of (±)-TRA is preferable for patients with a compromised swallowing
function. However, the stability of (±)-TRA in aqueous solution has yet to be determined in a clinical setting. The
aim of this study was to evaluate the photostability of (±)-TRA in aqueous solution in a clinical setting.
Methods: We improved high performance liquid chromatography (HPLC) method for the enantiomeric separation
of (±)-TRA, and then the (±)-TRA concentration was determined using HPLC method. We investigated the
photodegradation of (±)-TRA in an aqueous solution irradiated with ultraviolet (UV) light: UV-A, UV-B, and UV-C. We
also evaluated the stability of liquid formulations of (±)-TRA in a clinical setting by keeping (±)-TRA aqueous solution
in normal dispensing bottles and in light-shading dispensing bottles under conditions of both sunlight and diffused
light in a room. Samples were collected sequentially over time.
Results: (±)-TRA in aqueous solution was degraded the most rapidly when irradiated with UV-C, but was not affected
by irradiation with UV-A. No significant difference was observed in the photodegradation behavior of (+)-TRA and
(−)-TRA with UV-A, UV-B, and UV-C irradiation. The residual percentages of (±)-TRA were 94.6-104.3% after 14 days in
the presence of either sunlight or diffused light in a room, with or without protection from light.
Conclusions: These results demonstrated the stability of (±)-TRA in aqueous solution to both sunlight and diffused
light in a room. Therefore, liquid formulations of TRA are preserved at room temperature for up to 2 weeks, with or
without protection from light. Our results provide additional treatment options with tramadol for pain control.
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Tramadol hydrochloride (TRA), (1RS, 2RS)-2-[(dimethylamino)
methyl]-1-(3-methoxyphenyl) cyclohexanol hydrochloride,
is categorized as a weak opioid on the second step of the
three-step analgesic ladder for cancer pain relief by the
World Health Organization (WHO). It has been recom-
mended for the treatment of mild to moderate cancer pain
[1]. (±)-TRA achieves its analgesic effects by increasing
both serotonin and noradrenaline concentrations in
the synaptic cleft of neurons in the central nervous
system [2-4]. (+)-TRA mainly inhibits serotonin reuptake,
while (−)-TRA chiefly blocks noradrenaline reuptake. TRA
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unless otherwise stated.containing agents, and is generally used to relieve pain
associated with cancer and post-operative pain [5]. Accord-
ing to the WHO, analgesics for cancer should be adminis-
tered orally [1]. Oral liquid formulations are preferable for
patients with a compromised swallowing function, such as
the elderly or cancer patients, including those with laryn-
geal and oropharyngeal cancers [6-11].
The photodegradation of (±)-TRA by ultraviolet (UV)
irradiation is known to follow a first-order reaction
[12-14]. However, the stability of (±)-TRA in aqueous
solution in the presence of either sunlight or diffused
light has not yet been examined in detail. The storage
environment has the potential to have marked effects
on the quality of TRA liquid formulations.
The aim of this study was to evaluate the photostability
of (±)-TRA in aqueous solution in a clinical setting. We
investigated the photodegradation behavior of (±)-TRA inhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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We also evaluated the stability of (±)-TRA in aqueous
solution to light when stored in two conditions, involv-
ing sunlight and diffused light in a room for 2 weeks.
Methods
Chemicals and materials
Tramadol (TRA) capsules (tramal® capsules 25 mg;
Nihon Shinyaku, Japan) were obtained for the preparation
of (±)-TRA in aqueous solution. TRA hydrochloride (LKT
Laboratories, MN) was used as the reference standard.
Propranolol (Tokyo Kasei, Japan) was used as the internal
standard. Acetonitrile and methanol (Merck, Germany)
were products graded for high performance liquid chro-
matography (HPLC). Ammonium formate and diethylamine
(Sigma-Aldrich, MO) were obtained for HPLC. Ultrapure
water (Wako, Japan) was used to dissolve ammonium
formate. Ultraviolet (UV) irradiation was carried out
with a UV-A lamp (FL15BL, 15 W, dominant wavelength
352 nm,wavelength range 300–400 nm; Toshiba, Japan), a
UV-B lamp (GL15E, 15 W, dominant wavelength 306 nm,
wavelength range 280–320 nm; Sankyo, Japan), and a
UV-C lamp (GL-15, 15 W, dominant wavelength 253.7 nm;
Toshiba, Japan). A fluorescent lamp (FHF32EX-N-H, 32 W,
wavelength range 400–700 nm; Panasonic, Japan) was used
for diffuse light.
Preparation of (±)-TRA in aqueous solution
(±)-TRA in aqueous solution was prepared by emptying
the contents of four TRA capsules into 40 mL of Milli-Q
and filtering the solution with filter paper (Advantec,
Japan). Normal dispensing bottles (NDBs) (M.I-chemical,
Japan) were used for (±)-TRA in aqueous solution under
the conditions of UV irradiation, and light-shading dis-
pensing bottles (LSDBs) (M.I-chemical, Japan) as well as
NDBs were used for (±)-TRA in aqueous solution under
the conditions of both sunlight and diffused light in a
room.
Assay for (±)-TRA
(±)-TRA was resolved optically. A peak height ratio analysis
was employed to calculate the concentration of (+)-TRA
and (−)-TRA using (+)-propranolol and (−)-propranolol as
an internal standard, respectively. HPLC was performed
with a UV detector (UV-2075; Jasco, Japan), HPLC
pump (PU-2080; Jasco, Japan), and an analytical column
(CHIRALCEL OD-RH, 5 μm, 4.6 mm × 150 mm i.d.;
Daicel, Japan) in combination with a guard column
(CHIRALCEL OD-RH, 5 μm, 4.6 mm × 10 mm i.d.;
Daicel, Japan), and with a mobile phase of 5 mM ammo-
nium formate with 0.1% diethylamine in water/aceto-
nitrile (57:43, v/v), at 0.8 mL/min, 265 nm, and room
temperature. The run time was 30 min.Ten μL of the collected sample was pipetted into a 1.5 mL
polypropylene tube, and 480 μL of the mobile phase was
added and vortexed for 10 sec. Ten μL of (±)-propranolol as
an internal standard in methanol (1 μg/μL) was added to
the mixture and vortexed for 10 sec, and then a 10 μL
aliquot was injected onto the HPLC system.
Degradation of (±)-TRA in aqueous solution by UV-A,
UV-B, and UV-C irradiation
(±)-TRA in aqueous solution was irradiated with UV-A,
UV-B, and UV-C to analyze the photodegradation of
(±)-TRA in aqueous solution. The samples (each 300 μL)
were collected before and at 10, 20, and 30 min, 1, 2, 4, 6,
8, 24, and 48 h after UV-A, UV-B, and UV-C irradiation.
The samples were removed from the light and stored
at 5°C until analysis. The first-order reaction rate con-
stant (k) of (±)-TRA degradation in aqueous solution
by UV-A, UV-B, and UV-C irradiation was calculated.
Photostability of (±)-TRA in aqueous solution in a clinical
setting
NDBs and LSDBs were placed at a distance of 15 cm
from a window and maintained at room temperature
(20-25°C). The samples were irradiated by sunlight that
passed through the window and used to evaluate the
photostability of (±)-TRA in aqueous solution under the
condition of sunlight in a room. The measurement sam-
ples (each 300 μL) were collected at 0, 1, 2, 3, 5, 7, and
14 days after exposure to these conditions. The samples
were removed from the light and stored at 5°C until
analysis.
NDBs and LSDBs were placed at room temperature
(20-25°C), and darkness and irradiation with a fluores-
cent lamp light were alternated every 12 h to evaluate
the photostability of (±)-TRA in aqueous solution under
the condition of diffused light in a room. The samples
(each 300 μL) were collected at 0, 2, 4, 7, and 14 days
after exposure to these conditions. The samples were re-
moved from the light and stored at 5°C until analysis.
Statistical analysis
Statistical analyses were performed using SPSS (SPSS®
Statistics 22.0; IBM, Japan). The residual percentage
of (±)-TRA in aqueous solution was expressed as the
mean ± standard deviation (SD). In the experiment to
examine the photostability of (±)-TRA in aqueous solu-
tion in a clinical setting, repeated measures ANOVA was
used to compare the residual percentages of (±)-TRA in
aqueous solution at day 7 and 14 with that at day 0. The
unpaired t-test was performed to show the P-value be-
tween dispensing bottles, light conditions, and isomers
on day 14 in the comparison of residual percentages of





Figure 1 HPLC chromatogram of (±)-tramadol in aqueous
solution. Peak 1; (+)-tramadol, 2; (−)-tramadol, 3; (+)-propranolol,
and 4; (−)-propranolol.
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Chromatographic separation
(±)-TRA and (±)-propranolol separated well using the
HPLC conditions described above (Figure 1). The reten-
tion times of (+)-TRA, (−)-TRA, (+)-propranolol, and
(−)-propranolol in aqueous solution were 8.5, 9.5, 21.3,
and 24.0 min, respectively.
Calibration curve
The standard curves were expressed as the regression
equation of a straight-line, y = ax + b, where y is the con-
centration, a is the slope, x is the peak height ratio
against (±)-propranolol, and b is the y-axis intercept, by
the weighted liner regression analysis. The calibration curve,
which covered a concentration range of 5.0-100.0 ng/μL of
(±)-TRA exhibited linearity and had a coefficient of correl-
ation ((+)-TRA: y =0.0822x +0.0896, r =0.999, P <0.01, andTable 1 Accuracy and precision study on the (±)-tramadol ass
Nominal Run-to-run assay
concentration (ng/μL) Detected (ng/μL) Accuracy (%
(+)-tramadol 5.0 5.2 ± 0.1 103.4
10.0 9.5 ± 0.3 96.0
25.0 26.7 ± 0.4 103.9
50.0 50.4 ± 0.9 100.0
100.0 99.5 ± 2.2 100.3
(-)-tramadol 5.0 4.9 ± 0.2 94.8
10.0 9.5 ± 0.3 96.5
25.0 26.1 ± 0.9 104.5
50.0 50.7 ± 0.9 99.1
100.0 100.6 ± 2.1 101.2
Data are expressed as the mean ± SD of 6 analyses.
CV; coefficient of variation.(−)-TRA: y =0.0748x +0.0697, r =0.999, P <0.01). The
lower quantification limit of (±)-TRA was 5 ng/μL (signal
to noise; S/N >3).
Accuracy and precision
The accuracy and precision of the methods used was
confirmed at 5 different concentrations of (±)-TRA. The
method was reproducible with coefficients of validation
(CV) less than 5% for both intra- and inter-day variabil-
ity (Table 1). These values are in the acceptable range of
the US Food and Drug Administration guidance [15].
Photodegradation of (±)-TRA in aqueous solution by UV
irradiation
(±)-TRA in aqueous solution was degraded when irradi-
ated with UV-B and UV-C, but was not affected by irradi-
ation with UV-A. No significant difference was observed
in the photodegradation behavior of (+)-TRA or (−)-TRA
exposed to UV-A, UV-B, and UV-C irradiation (Figure 2).
The k values of (+)-TRA irradiated with UV-A, UV-B,
and UV-C were 1.00 × 10−3, 4.50 × 10−3, and 6.20 × 10−3
(h−1), respectively. The k values of (−)-TRA irradiated with
UV-A, UV-B, and UV-C were 0.40 × 10−3, 3.70 × 10−3, and
7.10 × 10−3 (h−1), respectively (Table 2). These results indi-
cated that (±)-TRA in aqueous solution was degraded the
most rapidly by UV-C irradiation.
Photostability of (±)-TRA in aqueous solution in a clinical
setting
(±)-TRA in NDBs was slightly degraded under the con-
dition of sunlight in a room (Figure 3). No significant
difference was observed in the residual percentages of
(±)-TRA between day 0 and 7 in NDBs under these con-
ditions. On the other hand, a significant reduction in the
residual percentages of (±)-TRA was observed between
day 0 and 14 in NDBs under these conditions ((+)-TRA;ay
Day-to-day assay
) CV (%) Detected (ng/μL) Accuracy (%) CV (%)
1.91 5.2 ± 0.1 104.3 1.90
3.29 9.6 ± 0.3 94.9 3.16
1.56 26.0 ± 0.6 104.0 2.89
1.70 50.0 ± 0.8 100.8 1.41
2.20 100.3 ± 2.8 99.5 2.80
4.10 4.7 ± 0.2 98.0 4.30
2.79 9.4 ± 0.2 94.5 2.25
3.44 26.1 ± 0.3 104.4 1.18
1.82 49.6 ± 0.4 101.4 0.88













Irradiation time ( h )
Figure 2 Plot of ln C vs time for the detection of (±)-tramadol in aqueous solution irradiated by UV-A, UV-B, and UV-C. A: (+)-tramadol
in aqueous solution irradiated by UV-A (●), UV-B (○), and UV-C (□). B: (−)-tramadol in aqueous solution irradiated by UV-A (●), UV-B (○), and UV-C (□).
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not degraded under the condition of diffused light in a
room (Figure 3). No significant difference was observed
in the concentration of (±)-TRA in NDBs between day 0
and 7 or between day 0 and 14 under these conditions,
respectively. The residual percentages of (±)-TRA in
both NDBs and LSDBs were 94.6-104.3% after 14 days
under both conditions of sunlight and diffused light in a
room. No significant difference was observed in the re-
sidual percentages of (±)-TRA between either the dis-
pensing bottles or light conditions (Table 3-A). No
significant difference was also found between the re-
sidual percentages of (+)-tramadol and (−)-tramadol
(Table 3-B).
Discussion
The photodegradation of (±)-TRA in aqueous solution
proceeded the most rapidly when exposed to UV-C ir-
radiation whereas UV-A irradiation had no effect. No
significant difference was observed in the photodegrada-
tion behavior of (+)-TRA and (−)-TRA with each type of
UV irradiation.
Many pharmaceutical compounds in solution requir-
ing protection from light are degraded not only by UV-B
and UV-C irradiation, but also by UV-A irradiation
[16-20]. Such UV-sensitive pharmaceutical compounds
include amiodarone, dapsone, dexametazone, lacidipine, ler-
canidipine, naproxen, nifedipine, and pitavastatin [16-20].
Pitavastatin in solution is very sensitive to UV-A irradiation,
and the k of pitavastatin in solution when irradiated with
UV-A is approximately 1.3 h−1, which is considerably larger
than the k of (+)-TRA and (−)-TRA in our study [20]. We
found that (±)-TRA in aqueous solution was not degradedTable 2 First-order degradation rate constants for (±)-tramad
UV-A lamp
(n) k (h−1) r
(+)-tramadol (5) 1.00 × 10−3 −0.237
(−)-tramadol (5) 0.40 × 10−3 −0.127
k; first-order reaction rate constant, r; correlation coefficient.by irradiation with UV-A, confirming the stability of
(±)-TRA in aqueous solution to UV-A.
The mean residual percentages of (±)-TRA in aqueous
solution after 2 weeks in a clinical setting ranged from
94.6-104.3%, although a significant reduction was ob-
served between day 0 and 14 under the condition of
sunlight in a room (Figure 3-A and -B). The range of the
mean residual percentages satisfied the United States
Pharmacopeia uniformity of content for liquid orals that
range from 85-115% [21]. These results demonstrate the
stability of liquid formulations of TRA for 2 weeks in a
clinical setting. Our results indicate that the mean re-
sidual percentages of (±)-TRA in aqueous solution
under the condition of sunlight in a room ranged from
94.6-100.2%. UV contained within sunlight has been
categorized into 3 main types of UV-A, UV-B, and
UV-C [22]. The percentages of UV-A and UV-B con-
tained within sunlight reaching the ground are ap-
proximately 5.3% and 0.14%, respectively, while UV-C
does not reach the ground due to its complete absorp-
tion in the atmosphere [23,24]. Therefore, the photo-
degradation of pharmaceutical compounds under the
condition of sunlight in a room was thought to be at-
tributed to mainly UV-A. Our results indicated that
the photodegradation of (±)-TRA in aqueous solution
was not caused by UV-A irradiation, which explains
the stability of (±)-TRA in aqueous solution under the
condition of sunlight in a room. The mean residual per-
centages of (±)-TRA in aqueous solution under the condi-
tion of diffused light in a room ranged from 99.2-104.3%.
The wavelength region of the fluorescent lamp used under
the condition of diffused light was longer than UV-A, and
the photodegradation of (±)-TRA in aqueous solutionol in aqueous solution exposed to UV irradiation
UV-B lamp UV-C lamp
k (h−1) r k (h−1) r
4.50 × 10−3 −0.881 6.20 × 10−3 −0.953












































Figure 3 Time courses of the residual percentages of (±)-tramadol in aqueous solution contained in normal dispensing bottles (NDBs)
and in light-shading dispensing bottles (LSDBs) under the conditions of both sunlight and diffused light in a room. A: (+)-tramadol in
aqueous solution contained in NDBs (○) and in LSDBs (●) under the conditions of sunlight in a room. B: (−)-tramadol in aqueous solution
contained in NDBs (○) and in LSDBs (●) under the conditions of sunlight in a room. C: (+)-tramadol in aqueous solution contained in NDBs (□) and
in LSDBs (■) under the conditions of diffused light in a room. D: (−)-tramadol in aqueous solution contained in NDBs (□) and in LSDBs (■) under the
conditions of diffused light in a room. The plots represent the mean ± SD. The residual percentages of (±)-tramadol in aqueous solution at day 7 and
14 were compared with day 0 by the repeated measures ANOVA. A significant reduction in the residual percentages of (±)-TRA was observed
between day 0 and 14 in NDBs under the condition of sunlight in a room (*P <0.05).
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ation. These results suggest that liquid formulations of
TRA are stable at room temperature for 2 weeks, with or
without protection from light.
This study evaluated the photostability of (±)-TRA in
aqueous solution in a clinical setting. We showed stabil-
ity of the liquid formulations of TRA for 2 weeks. It
should be noted that this study has the limitation that
the microbiological safety was not assessed. Therefore,Table 3 Residual percentages of (±)-tramadol in aqueous solu
(A) Comparison of dispensing bottles and light conditions
(n) NDBs
(±)-tramadol (Sunlight) (5) 94.6 ± 3.1
(±)-tramadol (Diffused light) (5) 103.4 ± 15.9




(+)-tramadol (5) 94.6 ± 3.4
P =0.97
100.2 ± 3.4
(−)-tramadol (5) 94.7 ± 2.4 99.6 ± 1.7
NDBs: normal dispensing bottles.
LSDBs: light-shading dispensing bottles.
The unpaired t-test was performed to calculate the P-value between the dispensingfurther evaluation of the microbiological safety of (±)-TRA
in aqueous solution will be necessary.
Conclusions
Our results indicated that the photodegradation of (±)-TRA
in aqueous solution proceeded the most rapidly by UV-C
irradiation whereas UV-A irradiation had no effect on
its stability. The photodegradation of (±)-TRA in aqueous
solution did not proceed in a clinical setting, whichtion in a clinical setting at day 14






100.9 ± 15.3 0.82








102.4 ± 14.5 99.2 ± 14.4
bottles, light conditions, and isomers.
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Our results demonstrate the stability of liquid formula-
tions of TRA at room temperature for 2 weeks, and pro-
vide additional treatment options to relieve pain in
patients with a compromised swallowing function.
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